Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Q2 2025 Earnings Call Transcript August 5, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $6.02, expectations ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales offset higher operating expenses due in part to development of experimental ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Thousand Oaks-based Amgen saw shares dip about 5% on Aug. 6, the day after the company’s earnings announcement, though not because of the earnings themselves but rather about news of its weight-loss ...

Amgen’s diversified portfolio strategy continues to hinge on a balance between high-margin legacy biologics, expanding biosimilar offerings, and innovative pipeline investments. Repatha and BLINCYTO ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Thankfully, some income stocks on the market don't have these issues, and their shares are worth holding on to forever. Let's ...